ABT News 40.01 10/16/2014 04:23:24 Abbott Laboratories (ABT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 40.01 $ABT

Look for Shares of Abbott Laboratories to Potentially Rebound after Yesterday's 2.56% Sell Off
Comtex SmarTrend(R) - Wed Oct 15, 4:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.36 to a high of $40.53. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $40.87 on volume of 9.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 40.01 (-1.05)

Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 40.01 (-1.05), AZN: 68.41 (-1.40), PFE: 28.19 (-0.27), SHPG: 170.49 (-74.08), SLXP: 132.42 (-1.16), MYL: 47.38 (+0.56), ABBV: 54.63 (+0.50)

China Interventional Cardiovascular Device Industry Report 2014-2017
M2 - Wed Oct 15, 8:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vk2z4c/china) has announced the addition of the "China Interventional Cardiovascular Device Industry Report,2014-2017" report to their offering. The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion. At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan. Affected by the implementation of Regulations on the Centralized Procurement of High-value Medical Consumables, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017. China Interventional Cardiovascular Device Industry Report, 2014-2017 focuses on the following: - Status quo of China interventional cardiovascular device industry, including overview, market demand, import & export, competitive landscape and entry barriers; - Development environment of China interventional cardiovascular device industry, embracing macro environment, policy climate and upstream & downstream sectors; - Status quo, competitive landscape, etc. of China interventional cardiovascular device market segments, covering coronary stent, balloon catheter, catheter, guidewire, sheath group and auxiliary devices; - Operation, interventional cardiovascular device business, etc. of 6 foreign and 12 Chinese interventional cardiovascular device companies. Key Topics Covered: 1. Overview of Interventional Cardiovascular Device Industry 2. Status Quo of China Interventional Cardiovascular Device Industry 3. Development Environment of China Interventional Cardiovascular Device Industry 4. Market Segments of China Interventional Cardiovascular Device Industry 5. Foreign Companies in China 6. Major Domestic Companies 7 Forecast and Outlook Companies Mentioned - Abbott Laboratories - AmsinoMed Medical Device - B. Braun - Boston Scientific - Dalian Yinyi - Demax Medical - JW Medical - Johnson & Johnson - Lepu Medical - Lifetech Scientific - Medtronic - MicroPort - Neich Medical (Shenzhen) - SCW Medicath - Sino Medical - Starway Medical - Synexmed - Terumo For more information visit http://www.researchandmarkets.com/research/vk2z4c/china
BSX: 11.44 (-0.12), JNJ: 98.21 (+1.20), ABT: 40.01 (-1.05), MDT: 62.25 (-1.26)

Global Partial Seizure Clinical Trials Review, H2, 2014
M2 - Wed Oct 15, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8gwn27/partial_seizure) has announced the addition of the "Partial Seizure Global Clinical Trials Review, H2, 2014" report to their offering. Partial Seizure Global Clinical Trials Review, H2, 2014 provides data on the Partial Seizure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Partial Seizure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Partial Seizure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Partial Seizure Therapeutics Clinical Trials - UCB S.A. - Pfizer Inc. - Eisai Co., Ltd. - Novartis AG - Johnson & Johnson - GlaxoSmithKline plc - Bial - Portela & Ca, S.A. - SK Holdings Co., Ltd. - Upsher-Smith Laboratories, Inc. - Abbott Laboratories - National Institute of Neurological Disorders and Stroke - Emory University - Oregon Health & Science University - Kyoto University - National Center for Complementary and Alternative Medicine - Hadassah Medical Organization - University of Pennsylvania - Lawson Health Research Institute - Massachusetts General Hospital - University of California, Davis For more information visit http://www.researchandmarkets.com/research/8g...al_seizure
JNJ: 98.21 (+1.20), ABT: 40.01 (-1.05), PFE: 28.19 (-0.27), GSK: 43.13 (-0.55), NVS: 86.22 (-0.65)

Affordable Housing Project, Lawsuit Settlement, Drug Review, and Earnings Release Schedules - Research Reports on UnitedHealth, Bristol-Myers, Boston Scientific, Abbott and Illumina
PR Newswire - Tue Oct 14, 7:55AM CDT
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7151-100free.
BSX: 11.44 (-0.12), ABT: 40.01 (-1.05), UNH: 82.16 (-0.66), ILMN: 153.59 (+4.47), BMY: 48.96 (+0.04)

Global Low-Calorie Food Market Outlook 2019 - Key Analysis of the $7.4 Billion Industry
M2 - Tue Oct 14, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7xnwf/lowcalorie_food) has announced the addition of the "Low-calorie Food Market - Global Forecast, Share, Size, Growth and Industry Analysis, 2014 - 2019" report to their offering. The global low-calorie food market was USD 7,418.6 million in 2013. Sucralose is expected to be the fastest growing segment, likely to register a strong growth in the future. Usage of low-calorie food products in the beverages sector is forecasted to increase by 5.9% CAGR from 2014 to 2019. Based on application the low calorie food market is broadly classified under, food, beverages, healthcare, tabletop and others. On the basis product segment, Aspartame, Sucralose, Stevia, Saccharin and Cyclamate are the broad categories. Aspartame is one of the most widely used artificial sweeteners. In the recent scenario, sucralose is gaining more popularity than aspartame. Growing consumer preferences for all-natural products have created a huge demand for stevia. Due to its growing popularity as a 100% natural sweetener, stevia is giving tough competition to other high-intensity sweeteners such as aspartame, saccharin and sucralose. The U.S. is the largest market for low calorie food, followed by the European countries. The developing nations in the Asia-Pacific region are expected to show high growth in the next five years. Some of the major companies operating in the market are PepsiCo Inc., The Coca-Cola Company, Groupe Danone, Bernard Food Industries, Inc., Nestle S.A., Ajinomoto Co., Inc., McNeil Nutritionals, LLC and Cargill, Incorporated. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Low-calorie Food Market - Industry Overview Chapter 4 Low-calorie Food Market- Product Segment Analysis Chapter 5 Low-calorie Food Market: by Application Chapter 6 Low-calorie Food Market- Regional Analysis Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Abbott Laboratories - Ajinomoto Co., Inc. - Bernard Food Industries, Inc. - Cargill, Incorporated - Dr Pepper Snapple Group Inc. - Groupe Danone - McNeil Nutritionals LLC - Nestle SA - PepsiCo, Inc. - The Coca-Cola Company - Zydus Wellness Ltd. For more information visit http://www.researchandmarkets.com/research/t7...lorie_food
ABT: 40.01 (-1.05), PEP: 91.77 (-1.24)

InvestorsObserver releases comments on Google, Wells Fargo, eBay, Abbott Labs, and Netflix
PR Newswire - Mon Oct 13, 8:31AM CDT
InvestorsObserver.com releases its Stocks To Watch guide.
NFLX: 448.59 (-0.53), ABT: 40.01 (-1.05), EBAY: 50.24 (-0.35), WFC: 47.85 (-0.98), GOOGL: 540.73 (-7.96)

3 Big Stocks to Buy in a Volatile Market
at The Street - Fri Oct 10, 12:34PM CDT
This week's volatile selling spree could be just the beginning.
RAI: 57.34 (-1.06), ABT: 40.01 (-1.05), DLR: 63.65 (-0.75)

Abbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors
PR Newswire - Fri Oct 10, 9:36AM CDT
Abbott (NYSE: ABT) and the World Marathon Majors announced a new partnership with Abbott becoming the race series' first-ever title sponsor. The series - comprising six of the largest and most renowned marathons in the world: Tokyo, Boston, Virgin Money London, BMW BERLIN, Bank of America Chicago and TCS New York City Marathon - will be renamed the Abbott World Marathon Majors starting in 2015.
ABT: 40.01 (-1.05)

Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 10, 7:50AM CDT
Amgen 's Enbrel hasn't been able to keep pace with AbbVie 's Humira, managing $4.2 billion in U.S. sales last year compared to Humira's $5.2 billion. So what's Amgen to do? Make a copycat of Humira, of course. You're not seeing double. ...
ABT: 40.01 (-1.05), AMGN: 130.90 (-1.30), ABBV: 54.63 (+0.50)

How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 60.19 (-0.91), ABT: 40.01 (-1.05), QLTI: 3.96 (-0.09), ACT: 217.24 (-4.83), AUXL: 30.41 (-0.46)

Global Biological Drugs Market Outlook 2020
M2 - Thu Oct 09, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv5tsf/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market. Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/sv...ical_drugs
BIIB: 305.69 (+4.11), ABT: 40.01 (-1.05), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), BMY: 48.96 (+0.04), NVS: 86.22 (-0.65)

New Frontiers in the US Clinical Chemistry and Immunodiagnostic Markets 2014: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Oct 08, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/smq5b7/new_frontiers_in) has announced the addition of the "New Frontiers in the US Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. New Frontiers in the U.S. Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape; is Venture Planning Group's new study of the major business opportunities emerging in the U.S. clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the U.S. market; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables. U.S. Market Overview - Estimates of facilities performing clinical chemistry and immunodiagnostic tests. - Test volume and sales projections. Strategic Recommendations - New product development opportunities with significant market appeal. - Alternative market penetration strategies. - Potential market entry barriers and risks. Market Segmentation Analysis - Comprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers. - Test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, by market segment:? Hospitals ? Commercial/Private Laboratories ? Physician Offices/Group Practices The companies analyzed in the report include: - Abbott Laboratories - AdnaGen - Agilent Technologies - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio/Innogenetics - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/sm...ontiers_in
ABT: 40.01 (-1.05), A: 51.79 (unch), DGX: 57.71 (-0.14), DHR: 71.98 (-0.02)

Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.55 (+0.02), ABT: 40.01 (-1.05), BMY: 48.96 (+0.04)

ISRG - Stunning Visualizations Pinpoint Hidden Risk
OptionVol - Mon Oct 06, 5:05PM CDT
This visualization is provided by: Capital Market Laboratories: Get Notified When CML Light Goes Live ISRG is trading $486.58, up 2.4% with IV30™ up 8.4%. The Symbol Summary is included below. Provided by Livevol Conclusion Relativ...
1 Comment
ISRG: 460.14 (-1.17), ABT: 40.01 (-1.05), BCR: 147.79 (-2.93), MDT: 62.25 (-1.26)

After Yesterday's Rally of 1.36% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 06, 4:00PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $41.99 to a high of $42.47. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $42.06 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 40.01 (-1.05)

Abbott Laboratories (ABT) Approaches New Upside Target of $42.23
Comtex SmarTrend(R) - Mon Oct 06, 11:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $41.64 today and have reached the first resistance level of $42.01. Should the shares continue to rise, the resistance pivots of $42.23 and $42.82 will be of interest.
ABT: 40.01 (-1.05)

Becton Buyout Of CareFusion Drives Up Both Stocks
at Investor's Business Daily - Mon Oct 06, 10:47AM CDT
Medical equipment makers Becton Dickinson (BDX) and CareFusion hit new highs on the stock market today after their $12.2 billion buyout deal was announced Sunday evening. On a conference call with analysts Monday morning, company leaders said the two...
ZMH: 97.72 (+0.18), ABT: 40.01 (-1.05), BDX: 124.53 (-0.54), MDT: 62.25 (-1.26), CFN: 56.69 (-0.26), COV: 85.86 (-6.50), SYK: 79.48 (-1.16)

Jazz Pharmaceuticals Uses New Cash To Buy For Growth
at Investor's Business Daily - Fri Oct 03, 1:39PM CDT
Just a few years ago, one drug generated all but a small slice of revenue for Jazz Pharmaceuticals. And though the drug, Xyrem, targeted a small patient population of narcolepsy sufferers -- people prone to fall suddenly asleep in the middle of the...
AGN: 177.59 (-4.40), ABT: 40.01 (-1.05), VRX: 114.34 (-0.60), MDT: 62.25 (-1.26), COV: 85.86 (-6.50), SHPG: 170.49 (-74.08), JAZZ: 146.31 (+2.58), HZNP: 10.91 (+0.30), MYL: 47.38 (+0.56), ABBV: 54.63 (+0.50), CNCE: 13.18 (+0.79)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Dyne Therapeutics Faces Legal Inquiry Amid FDA Approval Delays

Updated Category News Views 189

Understanding the Investigation Surrounding Dyne Therapeutics Recently, Pomerantz LLP, a recognized law firm, initiated an investigation on behalf of investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). The focus of this inquiry is on whether Dyne and its executives have participated in unlawful business practices, including securities fraud. These claims arise amidst...

Continue Reading
ThermAI Secures Major Investment from Tech Visionary Daniel Keller

Updated Category News Views 334

ThermAI's Innovative Breakthrough in Heat Recovery Technology ThermAI, a groundbreaking decentralised compute and heat-recovery protocol, has recently secured a strategic investment from Daniel Keller, a prominent figure in the tech industry known for co-founding Flux and playing a pivotal role in architecting Zelcore. This partnership is set to expedite ThermAI's...

Continue Reading
CAPTRUST Expands Reach with Carolinas Investment Consulting

Updated Category News Views 119

CAPTRUST Welcomes Carolinas Investment Consulting CAPTRUST Financial Advisors, known for their commitment to excellent service in the financial advisory realm, is embracing a new chapter with the addition of Carolinas Investment Consulting (CIC). This collaboration aims to deliver enhanced investment consulting and financial planning services to an even broader clientele....

Continue Reading
Essential Vehicle Preparations for College Students

Updated Category News Views 141

Get Your Car Ready for College Mercury Insurance Provides a Checklist to Make Sure You're Prepared As the academic year approaches, it's that time when students gear up to head back to campus. Whether you're a parent assisting your child or a student planning to drive yourself, it's crucial to ensure that your vehicle is ready for the journey ahead. Understanding this...

Continue Reading
Cineverse Unveils cineSearch: Revolutionizing Streaming Search

Updated Category News Views 406

Cineverse Introduces cineSearch for Enhanced Content Discovery AI-Powered cineSearch Unlocks Personalized Content Recommendations Across Leading Streaming Platforms Cineverse Corp. (NASDAQ: CNVS), an innovative streaming technology and entertainment company, is excited to announce the public preview of cineSearch, its groundbreaking AI-driven content discovery tool....

Continue Reading